POLARITYTE INC. - COMMON STOCK (PTE)
(Delayed Data from NSDQ)
$8.57 USD
-1.12 (-11.56%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.54 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
RegenETP, Inc. [PTE]
Reports for Purchase
Showing records 1 - 16 ( 16 total )
Company: RegenETP, Inc.
Industry: Medical - Drugs
Company: RegenETP, Inc.
Industry: Medical - Drugs
Study in DFU Patients to Initiate Imminently; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: RegenETP, Inc.
Industry: Medical - Drugs
Awaiting Regulatory Clarity on SkinTE; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: RegenETP, Inc.
Industry: Medical - Drugs
Company: RegenETP, Inc.
Industry: Medical - Drugs
Company: RegenETP, Inc.
Industry: Medical - Drugs
Awaiting SkinTE IND in 2H21; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: RegenETP, Inc.
Industry: Medical - Drugs
SkinTE IND to Be Filed in 2H21; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: RegenETP, Inc.
Industry: Medical - Drugs
Waiting for Clarity on SkinTE?s Regulatory Pathway; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: RegenETP, Inc.
Industry: Medical - Drugs
Positive Interim DFU Data; Questions Regarding SkinTE Future Remain; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: RegenETP, Inc.
Industry: Medical - Drugs
Waiting for Regulatory Clarity on SkinTE; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: RegenETP, Inc.
Industry: Medical - Drugs
Strategy Shift Adds Uncertainties; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: RegenETP, Inc.
Industry: Medical - Drugs
Expect COVID-19 Impact on Revenues to Be Temporary; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: RegenETP, Inc.
Industry: Medical - Drugs
Light 4Q19 but Growth Is Expected to Return; Lower PT to $5.00 on Dilution; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: RegenETP, Inc.
Industry: Medical - Drugs
SkinTE Sales Continue to Ramp; Clinical Updates in 2020; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: RegenETP, Inc.
Industry: Medical - Drugs
Promising Growth in SkinTE Sales; Clinical Updates in Near Term; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: RegenETP, Inc.
Industry: Medical - Drugs
|